Binjie Lu1, Qingkun Gao2, Rui Liu3, Ming Ren4, Yan Wu2, Zaixing Jiang5, Yi Zhou2. 1. Department of Ophthalmology, Central Laboratory, The First Clinical Hospital Attached to Harbin Medical University Harbin 150000, China. 2. Department of Thyroid and Breast Diseases, Central Laboratory, Cell Transplantation Key Lab Attached to Ministry of Public Health, The First Clinical Hospital Attched to Harbin Medical University Harbin 150000, China. 3. Department of General Surgery, The First Clinical Hospital Attached to Harbin Medical University Harbin 150000, China. 4. Department of Anesthesiology, Central Laboratory, The First Clinical Hospital Attached to Harbin Medical University Harbin 150000, China. 5. Department of Polymer Science and Technology, School of Chemical Engineering and Technology, Harbin Institute of Technology Harbin 150000, China.
Abstract
OBJECTIVE: This study aimed to develop a novel release system for grafted islets. MATERIALS AND METHODS: A graphene oxide-FTY720 release system was constructed to test the drug loading and releasing capacity. The recipient rats were divided into four groups as following: Experiment group A (EG A) and B (EG B); Control group A (CG A) and B (CG B). In each group, (2000 ± 100) IEQ microencapsulated islets were implanted into the abdominal cavity of the recipients with oral FTY720, local graphene oxide-FTY720 injection, without immunosuppressants, and with graphene oxide-saturated solution respectively. We detected the immunological data, the blood glucose level, and pericapsular overgrowth to show the transplantation effect. RESULTS: 31% of adsorptive FTY720 was released within 6 h, and 82% of FTY720 was released within 48 h. From day 5 to 8, the amount of PBL in EG B was significantly less than those in EG A (P<0.01). The CD3+ and CD8+ T lymphocytes were suppressed 3 days longer in EG B than in EG A. On day 19 posttransplantation, the blood glucose level in EG B was much lower than that in EG A (P<0.01). On the same day, pericapsular overgrowth was grade I in EG B, grade II in other groups. CONCLUSIONS: Graphene oxide-FTY720 complex showed a drug releasing effect. Local application of graphene-FTY720 releasing system could decrease the amount of peripheral blood lymphocytes (PBL) and the percentage of CD3 and CD8 T lymphocytes in blood for longer time than oral drug application. This releasing system could achieve a better blood glucose control.
OBJECTIVE: This study aimed to develop a novel release system for grafted islets. MATERIALS AND METHODS: A graphene oxide-FTY720 release system was constructed to test the drug loading and releasing capacity. The recipient rats were divided into four groups as following: Experiment group A (EG A) and B (EG B); Control group A (CG A) and B (CG B). In each group, (2000 ± 100) IEQ microencapsulated islets were implanted into the abdominal cavity of the recipients with oral FTY720, local graphene oxide-FTY720 injection, without immunosuppressants, and with graphene oxide-saturated solution respectively. We detected the immunological data, the blood glucose level, and pericapsular overgrowth to show the transplantation effect. RESULTS: 31% of adsorptive FTY720 was released within 6 h, and 82% of FTY720 was released within 48 h. From day 5 to 8, the amount of PBL in EG B was significantly less than those in EG A (P<0.01). The CD3+ and CD8+ T lymphocytes were suppressed 3 days longer in EG B than in EG A. On day 19 posttransplantation, the blood glucose level in EG B was much lower than that in EG A (P<0.01). On the same day, pericapsular overgrowth was grade I in EG B, grade II in other groups. CONCLUSIONS:Graphene oxide-FTY720 complex showed a drug releasing effect. Local application of graphene-FTY720 releasing system could decrease the amount of peripheral blood lymphocytes (PBL) and the percentage of CD3 and CD8 T lymphocytes in blood for longer time than oral drug application. This releasing system could achieve a better blood glucose control.
Authors: Kenneth Cardona; Gregory S Korbutt; Zvonimir Milas; James Lyon; Jose Cano; Wanhong Jiang; Hameeda Bello-Laborn; Brad Hacquoil; Elizabeth Strobert; Shivaprakash Gangappa; Collin J Weber; Thomas C Pearson; Ray V Rajotte; Christian P Larsen Journal: Nat Med Date: 2006-02-26 Impact factor: 53.440
Authors: Evelina Vågesjö; Gustaf Christoffersson; Tomas B Waldén; Per-Ola Carlsson; Magnus Essand; Olle Korsgren; Mia Phillipson Journal: Cell Transplant Date: 2014-01-29 Impact factor: 4.064
Authors: Sakari Reitamo; Edwin J M Van Leent; Vincent Ho; John Harper; Thomas Ruzicka; Kirsti Kalimo; Frédéric Cambazard; Malcolm Rustin; Alain Taïeb; David Gratton; Daniel Sauder; Graham Sharpe; Catherine Smith; Michael Jünger; Yves de Prost Journal: J Allergy Clin Immunol Date: 2002-03 Impact factor: 10.793